Document is current

Article History

Accepted: 27 July 2025

First Online: 22 August 2025

Declarations

:

: This trial was financially funded by the company of Chiatai Qingchunbao Pharmaceutical Co., Ltd (Hangzhou, China).

: Yinglin Yang, Jiejing Kai, Duo Lv, Huili Zhou, Yan Yu, Jianzhong Shentu, and Guolan Wu have no conflicts of interest that are directly relevant to the content of this article.

: The final study protocol was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine on 15 November, 2018 (Approval No. 2018-EC-333).

: Before any procedures were performed, subjects signed a written informed permission and were allowed to withdraw from the study at any moment.

: Not applicable.

: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. For data access, please contact the corresponding author at yilanlan_001@163.com.

: Not applicable. The study used only licensed commercial software without any custom code.

: GW and JS were involved in the study’s conception, design, and planning. YY, JK, YY, and HZ were all involved in the clinical trial’s execution, data collection, and interpretation. DL was in charge of the research project’s quality control. YY and GW were responsible for the data analysis, findings interpretation, and manuscript drafting. All authors read and approved the final version.